Early action, lifelong impact: the crucial role of early detection, risk stratification, and aggressive treatment of familial hypercholesterolaemia

Eur J Prev Cardiol. 2024 May 11;31(7):889-891. doi: 10.1093/eurjpc/zwae068.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Biomarkers / blood
  • Early Diagnosis*
  • Genetic Predisposition to Disease
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Hyperlipoproteinemia Type II* / diagnosis
  • Hyperlipoproteinemia Type II* / genetics
  • Risk Assessment
  • Risk Factors

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Biomarkers